September 21, 2018 8:13am
FATE had closed at $14.03 (+$0.67 or +5.01%) and was down in the pre-market -$0.63 or -4.49%
FATE had 53.42 M shares outstanding, a float of 44.68 M and a 52 week change of +224.27% with a cash position of $78.02 M and $14.85 M in debt on the books
A good move after a market high and collaboration news with ONO Pharmaceuticals
FATE priced an underwritten public offering of 9,259,260 shares of its common stock at a public offering price of $13.50 per share, before underwriting discounts, for an aggregate offering of approximately $125.0 million.
FATE has granted the underwriters a 30-day option to purchase up to an additional 1,388,889 shares of its common stock.
The proceeds to FATE from this offering are expected to be approximately $117.2 million after deducting underwriting discounts and commissions and other estimated offering expenses but excluding any exercise of the underwriters’ option.
Jefferies, Piper Jaffray, and Wells Fargo Securities are acting as joint book-running managers for the offering. Wedbush PacGrow is acting as a co-manager for the offering.